IP Library Granted Patent US 7,884,205
Granted Patent B2
US 7,884,205 · App. 11/883,125 · Granted Feb 8, 2011

Salts of aripiprazole

Assignee: Sandoz AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,884,205
App. No.
11/883,125
Granted
Feb 8, 2011
Kind
B2
Abstract

The present invention relates to acid addition salts of aripiprazole, a process for preparing said acid addition salts and their use to prepare or purify aripiprazole in the form of a free base or in the form of a pharmaceutically acceptable salt.

Claims (18)

1. A process for the production of aripiprazole or a pharmaceutically acceptable salt thereof comprising the steps of preparing and isolating an oxalic acid addition salt of aripiprazole or a solvate thereof and converting the oxalic acid addition salt or solvate thereof into aripiprazole in free form with less than 0.1% (w/w) of a compound of formula VII

and optionally converting the free form aripiprazole into a pharmaceutically acceptable salt of aripiprazole.

2. A process for the production of aripiprazole or a pharmaceutically acceptable salt thereof comprising the steps of

a) reacting a compound of formula

with a compound of formula

wherein X and Z are the same or different and each denote a halogen atom, or a group which is similar to halogen groups suitable to undergo a substitution reaction, to obtain a compound of formula

wherein X denotes as in formula III,

b) reacting a compound of formula IV as obtained from step a) with a compound of formula

to obtain a compound of formula

c) isolating the compound of formula VI as obtained in step b) in the form of an acid addition salt of formula

or a solvate thereof wherein Ac is oxalic acid, and

d) converting an acid addition salt of formula VIII as obtained in step c) into a compound of formula VI to isolate aripiprazole in free form with less than 0.1% (w/w) of a compound of formula VII

which is optionally further converted into a pharmaceutically acceptable salt of aripiprazole.

3. The process according to claim 2 which does not comprise any purification step of a compound of formula IV before reacting it with a compound of formula V.

4. The process according to claim 3 wherein aripiprazole in free form is isolated with less than 0.05% (w/w) of a compound of formula VII.

5. A process for the purification of aripiprazote by preparing an acid addition salt of formula VIII as defined in claim 2 , isolating said acid addition salt and converting it into aripiprazole in free form.

6. The process according to claim 5 wherein the aripiprazole isolated in free form is an aripiprazole which is substantially pure in terms of crystalline form, by using appropriate seed crystals and containing less than 0.1% of a compound of formula VII.

7. The acid addition salt of formula VIII as defined in claim 1 which is used in the preparation of aripiprazole.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2009
From: LUDESCHER, JOHANNES; STURM, HUBERT
To: SANDOZ AG
Reel/Frame 022880/0145 →
Priority Claims (2)
EP 05001638 · Jan 27, 2005 · regional
EP 05001639 · Jan 27, 2005 · regional
Continuity (1)
Related Publication 20080287677A1 · Nov 20, 2008